KRAS and pancreatic intraductal papillary-mucinous neoplasm: Since KRAS mutations are present in over 90% of PDAC and considered to be an early event in the development of PDAC [33,34], this could be considered a sign of a higher occurrence of CECs in patients with premalignant IPMN lesions.